67results about "Mucins" patented technology

Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.

Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen are disclosed. Methods of treating a subject with a MUC16-expressing tumor and methods of preventing a MUC16-expressing tumor are disclosed. Modified consensus MUC16 antigen is disclosed.

The present invention relates to purified biocompatible mucus capable of forming a gel. The mucus of the present invention may be provided in a tissue model along with a cell population. The mucin or tissue model of the present invention may be useful in in vitro models of digestion, mucus penetration, and / or epithelial transport.

The invention provides a fusion protein with high repair capacity, a preparation method and application thereof, and belongs to the technical field of hybrid peptides. The amino acid sequence of the fusion protein is shown as SEQ ID NO.1; the fusion protein is obtained by sequentially connecting the following modules in series: a functional domain 1 of fibronectin, a hydrophilic region 1 of elastin, a functional domain 1 of mussel mucin, a hydrophilic region 2 of elastin, a functional domain 2 of fibronectin, a hydrophilic region 3 of elastin, a functional domain 2 of mussel mucin, a hydrophilic region 4 of elastin and an integrin binding region of elastin. The fusion protein of fibronectin, elastin and mussel mucin is constructed, and the nucleotide sequence of the fusion protein is optimized, so that the relative migration rate of keratinocytes can be obviously improved, the expression quantity of repair-related genes of HaCat cells can be improved, the secretion quantity of skin stimulating factors can be reduced, and the inhibition rate on hyaluronidase can be improved; the skin repairing and relieving capability is improved.

Provided herein are multiepitope peptides comprising at least one mucin 1 (MUC1) peptide, having MHC affinity for at least one HLA serotype, and recognized by CD4+ T cell receptors and / or CD8+ T cell receptors. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various embodiments, the cationic lipid is R-DOTAP. The present invention also provides methods of using the multiepitope peptides, as well as compositions and vaccine compositions. These methods of use include methods for treating cancer in a subject and methods for inducing MUC-specific polyfunctional and cytolytic T cell responses in a subject.

The present invention relates to a purified, biocompatible mucus, which has the ability to form a gel. The mucus of the invention may be provided in a tissue model, with a cell population. The mucin or tissue model of the invention may be useful in an in vitro model of digestion, mucus permeation and / or epithelial transport.

The present disclosure relates to engineered cells expressing heterologous MUC1, MUC1-C or MUC1-C cytoplasmic domain for generating induced pluripotent stem cells that are autologous to a subject.

Combination therapies and methods implementing the administration of a selective inhibitor of soluble tumor necrosis factor alpha (solTNF-a), preferably a dominant negative TNF-α protein, in combination with an anti-cancer therapeutic agent for treating MUC4+ cancer in human or animal subjects.

The present disclosure relates to chimeric Tim receptors, host cells modified to include chimeric Tim receptor molecules, and methods of making and using such receptor molecules and modified cells.

The present invention provides a peptide that includes eight or more consecutive amino acid residues of amino acid sequence of one of Sequence ID Nos. 1 to 12 and that consists of eleven or less amino acid residues.

The present invention relates to purified biocompatible mucus capable of forming a gel. The mucus of the present invention may be provided in a tissue model along with a cell population. The mucin or tissue model of the present invention may be useful in in vitro models of digestion, mucus penetration, and / or epithelial transport.

The present disclosure relates to chimeric Tim4 receptors, host cells modified to include chimeric Tim4 receptor molecules, and methods of making and using such receptor molecules and modified cells.

To provide anti-MUC16 antibodies and uses thereof.SOLUTION: Provided herein are a composition, a method and use related to an antibody that immunospecifically binds to a glycosylated form of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating or preventing disorders, such as cancer. Provided are antibodies or antigen binding fragments thereof, and polypeptides including such antibodies or antigen-binding fragments thereof, for example, fusion proteins, conjugates, and / or chimeric antigen receptors as well as cells expressing the same.SELECTED DRAWING: Figure 1A-B

A device is provided for detecting enzymatic activity in mucus layer. The device comprises at least one mucin molecule corresponding to an enzyme of a first type, wherein the mucin molecule is coupled to a surface of the device and is configured to be in contact with mucus layer contents, at least one probe coupled to an end of the mucin molecule opposite to the surface of the device, and a detector configured to detect a presence of the probe and / or a property of the probe in order to detect a status of the mucin molecule.

The invention relates to a matrix, in particular for forming a layer surrounding a target organism, comprising at least one matrix former and at least one bioeffector, a method for enriching bioeffectors on a target organism, the use of the matrix as an external layer for seeds, the use of the matrix as a carrier for bioeffectors and the matrix for use as a pharmaceutical.

The invention discloses a carrier for localizing a target protein on the surface of a cell membrane, the carrier comprises a Claudin18.2 1-27aa sequence, a PDGFR membrane localization sequence, multiple cloning sites and a gene for coding the target protein, the multiple cloning sites are located between the Claudin18.2 1-27aa sequence and the PDGFR membrane localization sequence, the gene for coding the target protein is inserted into the multiple cloning sites, and the nucleotide sequence of the Claudin18.2 1-27aa sequence is shown as SEQ ID No.6. The invention further discloses a preparation method of the carrier for localizing the target protein on the surface of the cell membrane. The molecular design of the vector fragment can efficiently and quickly locate the protein / polypeptide on the cell membrane surface, does not need to synthesize the full length of the protein, reduces the gene synthesis cost, and can be applied to production of liquid cell quality control products.

Disclosed herein are methods of decreasing mucus hypersecretion in the lungs comprising administering an effective amount of a MUC1 inhibitor to a subject in need thereof. In certain embodiments, the MUC1 inhibitor is the peptide GO-201, GO-203, or GO-203-2C. In certain embodiments, the subject is a human patient. In certain embodiments, the subject is diagnosed with rhinosinusitis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, or a respiratory syncytial virus (RSV) infection.

The present invention relates to a purified, biocompatible mucus, which has the ability to form a gel. The mucus of the invention may be provided in a tissue model, with a cell population. The mucin or tissue model of the invention may be useful in an in vitro model of digestion, mucus permeation and / or epithelial transport.

The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and / or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.

An oligonucleotide comprising a lipophilic monomer and a use thereof in non-liver delivery. Specifically, the present disclosure relates to an oligonucleotide, comprising an antisense strand complementary to a target gene, a sense strand complementary to the antisense strand, and one or more compounds represented by formula (I). The present disclosure further relates to a pharmaceutical composition comprising the oligonucleotide, and a medicinal use of the oligonucleotide and / or the pharmaceutical composition.

An anti-tumor fusion protein that can inhibit the growth of MUC1-positive tumor cells and can inhibit the growth of tumor cells in pancreatic cancer. This fusion protein has broad application prospects for the prevention and / or treatment of pancreatic cancer.

The invention belongs to the technical field of emulsions, and particularly relates to a double-emulsion, a probiotic-encapsulated double-emulsion and a preparation method and application of the double-emulsion. The double-emulsion provided by the invention is prepared by taking ultrasonic modified ovomucin as an outer layer to wrap water-in-oil type emulsion droplets and through two-step shearing and homogenizing, the preparation process flow is simple, the quality is easy to control, and the raw materials can be selected from food raw materials, so that the double-emulsion is safe and reliable. The double emulsion prepared by the preparation method can be used for encapsulating various substances such as water-soluble drugs and probiotics, has high encapsulation efficiency, can obviously improve the endurance capacity of the encapsulated substance to gastrointestinal digestive juice after oral administration, and improves the stability of the encapsulated substance in the gastrointestinal digestive juice. The probiotic-encapsulated double emulsion prepared on the basis of the double emulsion system can obviously improve the endurance capacity of the probiotics to various environments such as acidity, alkalinity, cholate, digestive enzymes and the like, and is helpful for the probiotics to exert effects in intestinal tracts.

The present disclosure relates to chimeric Tim receptors, host cells modified to include chimeric Tim receptor molecules, and methods of making and using such receptor molecules and modified cells.

The present invention relates to a compound comprising a first polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of -GFTFSDYW (SEQ ID NO: 1), IRLKSNNYAA (SEQ ID NO: 2) and TFGNSFAY (SEQ ID NO: 3), and a second polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of -TGAVTTNNY (SEQ ID NO: 4), GTN (SEQ ID NO: 5) and ALWYSNHWV (SEQ ID NO: 6), or a variant of any one of said amino acid sequences SEQ ID NO: 1 to SEQ ID NO: 6 having a different amino acid at one position, The present invention relates to compounds or variants that are capable of binding to tumor-associated mucin-1 (TA-MUC1). [Selected Figure] Figure 1

The present disclosure relates to chimeric Tim4 receptors, host cells modified to include chimeric Tim4 receptor molecules, and methods of making and using such receptor molecules and modified cells.

Provided herein are compositions, methods, and uses relating to antibodies that immunospecifically bind to glycosylated forms of MUC16, a tethered mucin. Also provided herein are uses and methods for managing, treating, or preventing a disease, e.g., cancer.

The invention discloses a method for heterologous expression of snail-derived mucoprotein and application of the snail-derived mucoprotein. The snail-source mucoprotein is derived from African large snails, and the amino acid sequence of the snail-source mucoprotein is shown as SEQ ID NO.1. The protein is expressed and fermented by pichia pastoris, and the yield is obviously improved by optimizing a signal peptide sequence and a purification method and can reach 5g / L or above; and the mucoprotein with the purity of more than 95% is obtained. The snail-derived mucoprotein is subjected to efficacy characterization in vitro and on the cellular level, and the result shows that the protein has a remarkable effect in the aspect of repairing and further has the effects of resisting oxidation, relieving, moisturizing and whitening. The method can be used as a substitute of existing snail mucus, and solves the problems that snail mucus extraction is difficult in large-scale production, large in batch difference, high in pathogen pollution risk, inconsistent with the animal welfare principle and the like. Therefore, the invention has great application potential in the aspects of cosmetics, medicines and the like.

Provided are compositions and methods related to modified lubricins, methods of making the modified lubricins, and methods of using the modified lubricins for coating a variety of inanimate objects, and for prophylaxis and / or therapy of disorders where enhanced lubrication of one or more parts of a human or non-human mammal is desirable.

Disclosed are compositions comprising glycopeptides obtained from gastrointestinal mucins that have superior microbiota affects, and methods of manufacture and use thereof. Such compositions are advantageous for pharmaceutical, food stuff and pet food applications.